Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL11457679 | 0.98 | HTR2C (0.34) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL118973 | 0.98 | HTR2C (0.34) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL27986246 | 0.98 | HTR2C (0.34) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| Iodide SCHEMBL11457678 | 0.64 | SLC18A3 (0.37) | — | |
| Hydrochloric Acid SCHEMBL6830548 | 0.64 | SLC18A3 (0.37) | — | |
| Hydrochloric Acid SCHEMBL22031619 | 0.63 | — | — | |
| Iodide SCHEMBL22031617 | 0.63 | — | — | |
| SCHEMBL4907271 | 0.63 | ORAI1 (0.40) | HTR2CHTR2ASLC6A2SLC6A4 | |
| SCHEMBL8331771 | 0.62 | — | — | |
| SCHEMBL5281905 | 0.61 | APOBEC3A (0.37) | HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026696-A1 | Novel Humic Material and Method to Formulate the Same | MEYER MICHAEL J (US) | 2025-01-23 | — | — | US | claimed |
| US-20230078902-A1 | Novel Method to Formulate Humic Substances | MEYER MICHAEL J (US) | 2023-03-16 | — | — | US | claimed |
| WO-2023279162-A1 | METHODS OF TREATMENT AND INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2023-01-12 | — | — | WO | claimed |
| US-11548833-B2 | Method to formulate humic substances | MEYER MICHAEL J (US) | 2023-01-10 | — | — | US | claimed |
| US-20200385320-A1 | Method to Formulate Humic Substances | MEYER MICHAEL J (US) | 2020-12-10 | — | — | US | claimed |
| US-10568852-B2 | Combination compositions and their use in methods for treating obesity and obesity-related disorders | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-02-25 | — | — | US | claimed |
| US-20180147163-A1 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-05-31 | — | — | US | claimed |
| EP-3297676-A2 | COMBINATION OF TRPM8-AGONIST AND NACHR-AGONIST FOR TREATMENT OF OBESITY AND RELATED DISORDERS AND FOR WEIGHT REDUCTION | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2018-03-28 | — | — | EP | claimed |
| US-20170348430-A1 | MICELAR DELIVERY SYSTEM BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID | RAMOT AT TEL AVIV UNlVERSITY LTD. (IL) | 2017-12-07 | — | — | US | claimed |
| EP-3191137-A1 | MICELAR DELIVERY SYSTEM BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID | Ramot at Tel-Aviv University Ltd. (IL) | 2017-07-19 | — | — | EP | claimed |
| EP-1773779-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2007-04-18 | — | — | EP | claimed |
| WO-2006005195-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITé LAVAL (CA) | 2006-01-19 | — | — | WO | claimed |
| WO-2005117860-A1 | METHOD OF TREATING AND PREVENTING ARTHRITIS, CUTANEOUS AND CARDIOVASCULAR INFLAMMATORY-RELATED DISEASES USING NICOTINIC RECEPTOR AGONISTS | ASMACURE LTÉE (CA) | 2005-12-15 | — | — | WO | claimed |
| US-20050130990-A1 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2005-06-16 | — | — | US | claimed |
| CN-1610714-A | Polycarbonate-siloxane copolymers | GEN ELECTRIC (US) | 2005-04-27 | — | — | CN | claimed |
| JP-2004523588-A | — | — | 2004-08-05 | — | — | JP | claimed |
| US-20040132737-A1 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2004-07-08 | — | — | US | claimed |
| CN-1498108-A | Nicotinic receptor agonists for treatment of inflammatory diseases | �Ϻ���ͨ��ѧ | 2004-05-19 | — | — | CN | claimed |
| EP-1370264-A2 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Université Laval (CA) | 2003-12-17 | — | — | EP | claimed |
| WO-2002076434-A2 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2002-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568852-B2 | Combination compositions and their use in methods for treating obesity and obesity-related disorders | FABP4, LIPC, GPR119 | HTR2C 1078/4885HTR2A 1019/4885HTR2B 1733/4885 |
| US-20180147163-A1 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | FABP4, LIPC, GPR119 | HTR2C 1078/4885HTR2A 1019/4885HTR2B 1733/4885 |
| US-20170348430-A1 | MICELAR DELIVERY SYSTEM BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID | KIT, JMJD7, LIPA | HTR2C 4393/4885HTR2A 4225/4885HTR2B 3793/4885 |
| US-20050130990-A1 | Nicotinic receptor agonists for the treatment of inflammatory diseases | CHRNA1, NR3C1, CHRNG | HTR2C 640/4885HTR2A 478/4885HTR2B 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.